Enanta Pharma

ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AIHS

ASST

BENF

BGSF

BURU

CETY

DLXY

EFTY

ENTA

FBIO

GLXG

MASK

QUAD

RVYL

SKYQ

Las acciones de Ryvyl Inc escalaron casi un 100 % en el premercado tras anunciar un acuerdo de fusión de 75 millones con RTB Digital.

Las acciones de Ryvyl se disparan un 97%; Aquí están 20 acciones que se mueven en el premarket

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharmaceuticals Inc

Entain PLC

Biotech's Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM,  ENTA)

Press Releases

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

Enanta Pharmaceuticals to Participate in September Investor Conferences

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

ARVN

MDCX

RYTM

Abeona Therapeutics

AC Immune

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Alector

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Altimmune

Annexon

Candel Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals

ETHZilla

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lyell Immunopharma

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

PepGen

Replimune Group

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tenaya Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Zura Bio Limited - Class A Ordinary shares

Zura Bio

WestPark Capital

Evercore ISI Group

JMP Securities

HC Wainwright & Co.

Comments

Enanta Pharma

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL